Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

RaphaelRapoport Dec. 25 at 2:03 AM

$CADL 6.35 afterhours is wild. I thought I saw bid at 6.47 -- ready to get back up there. Yum yum

0 · Reply

kinosouppp Dec. 25 at 12:58 AM

$CADL nice finish

0 · Reply

1iquid Dec. 25 at 12:31 AM

💎 Liquid® Live Actionable Trade Asset: $CADL Contracts: $CADL July 17, 2026 $7 Calls Scale in: $1.89- $2.31 Scale out: $7.35-$12.60 Profit Potential : 155% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

dirkfrank Dec. 24 at 10:47 PM

$CADL im a little bit confused

1 · Reply

Xanderzzzzzzz Dec. 24 at 10:04 PM

$CADL

0 · Reply

peapope Dec. 24 at 10:02 PM

$CADL 6.20 on the bid mofos Merry Xmas hahahahahahahahhaha

0 · Reply

Yeettrader Dec. 24 at 9:47 PM

$CADL to the bulls, I hope you have a merry Christmas! To the bears, I hope you had a happy Hanukkah!

0 · Reply

OtherOtttawaGuy Dec. 24 at 9:35 PM

$CADL Happy Ho-Ho from the "Great White North" eh...lol https://youtu.be/w1RN3cYnY9k?si=NWlyAbphm2SEUSj9

1 · Reply

MrsBelfort Dec. 24 at 9:32 PM

$CADL $ULTA Merry Christmas and Happy Holidays to all the longs. May 2026 bring health and happiness!

1 · Reply

Drcando Dec. 24 at 8:39 PM

$CADL Let's try an be sure an mash the 🐂 ish on all posts Let's get this off Bear 🐻

0 · Reply

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025, 8:25 AM EST - 5 weeks ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 7 weeks ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 7 weeks ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 2 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 2 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 13, 2025, 10:22 AM EDT - 2 months ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 3, 2025, 9:05 AM EDT - 2 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 7, 2025, 10:53 AM EDT - 3 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 5, 2025, 12:47 PM EDT - 3 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 2, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 6 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

May 28, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 7 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 13, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 9 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 9 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 10 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 10 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 4:52 PM EST - 10 months ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 20, 2025, 10:45 AM EST - 10 months ago

Candel Therapeutics: Entering Its Pivotal Year

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Dec 12, 2024, 11:00 PM EST - 1 year ago

Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 12:19 PM EST - 1 year ago

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11, 2024, 9:19 AM EST - 1 year ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 5, 2024, 9:00 AM EST - 1 year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Nov 1, 2024, 12:40 PM EDT - 1 year ago

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

RaphaelRapoport Dec. 25 at 2:03 AM

$CADL 6.35 afterhours is wild. I thought I saw bid at 6.47 -- ready to get back up there. Yum yum

0 · Reply

kinosouppp Dec. 25 at 12:58 AM

$CADL nice finish

0 · Reply

1iquid Dec. 25 at 12:31 AM

0 · Reply

dirkfrank Dec. 24 at 10:47 PM

$CADL im a little bit confused

1 · Reply

Xanderzzzzzzz Dec. 24 at 10:04 PM

$CADL

0 · Reply

peapope Dec. 24 at 10:02 PM

$CADL 6.20 on the bid mofos Merry Xmas hahahahahahahahhaha

0 · Reply

Yeettrader Dec. 24 at 9:47 PM

$CADL to the bulls, I hope you have a merry Christmas! To the bears, I hope you had a happy Hanukkah!

0 · Reply

OtherOtttawaGuy Dec. 24 at 9:35 PM

$CADL Happy Ho-Ho from the "Great White North" eh...lol https://youtu.be/w1RN3cYnY9k?si=NWlyAbphm2SEUSj9

1 · Reply

MrsBelfort Dec. 24 at 9:32 PM

$CADL $ULTA Merry Christmas and Happy Holidays to all the longs. May 2026 bring health and happiness!

1 · Reply

Drcando Dec. 24 at 8:39 PM

$CADL Let's try an be sure an mash the 🐂 ish on all posts Let's get this off Bear 🐻

0 · Reply

amessagefromtheodd Dec. 24 at 8:30 PM

$SLS I will tell you what $IOVA we must $KROS look after $CADL our own $VXRT The Saga Continues 2026

0 · Reply

badprecog Dec. 24 at 6:49 PM

$CADL Seems like a billion MC should be min right now

0 · Reply

Dkll303 Dec. 24 at 6:48 PM

$CADL YES ..TAK , hahahaha …. Or so they say… Yet , THE POS ..READ THIS CLOSELY without children THE POS CAN NOT MOVE . PROVOKE SHORTS , OR EVEN COME UP WITH A DATE FOR A BLA , OR NDA SUBMISSION

0 · Reply

Dkll303 Dec. 24 at 6:38 PM

$CADL And …seeing …….now only a mirage

0 · Reply

Dkll303 Dec. 24 at 6:33 PM

$CADL And @Stocksprofessional , clearly can read my ROI for 11 months of this pos …and YES, YOU SAW WHAT I SAID THE MASSIVE STOP SIGN POP UP AT $6.12 …KENNY G , stops this like the Hoover Dam !! lol Now, read it Mr @Stocksprofessional ….as for others that you mention , I read their posts like your pathetic pumping But , it didn’t work against me , lol …LOSER

0 · Reply

Drcando Dec. 24 at 6:33 PM

$CADL Merry Christmas 🎄 Everyone be careful No DWI's 🍻🥃🥂🍹🍸

0 · Reply

RaphaelRapoport Dec. 24 at 4:42 PM

$CADL Why is there a random wall at 6.13/6.14. Third time we're hitting this.

2 · Reply

Stocksprofessional Dec. 24 at 4:31 PM

$CADL Give them a round of applause!👏

3 · Reply

Drcando Dec. 24 at 4:27 PM

$CADL Merry Christmas 🎄 to everyone Let's hope an pray for a great cure to come through for our cancer friends an victims God Bless All 🎄🎄🎄

0 · Reply

Dkll303 Dec. 24 at 4:25 PM

$CADL …yes I’d agree , @Stocksprofessional . He is a moron ..believing that $6 or $6.12 can be held , hahaha He saw it two days ago, falter like an engine without POWER

1 · Reply

moneymaker444 Dec. 24 at 4:15 PM

$CADL on X from PPT

0 · Reply

Musky49 Dec. 24 at 3:59 PM

$CADL Locked and loaded. Thx D!!!

0 · Reply

Market Cap	322.25M
Revenue (ttm)	0.00
Net Income (ttm)	-55.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.06

Volume	345,800
Avg Vol	822,790
Day's Range	N/A - N/A
Shares Out	54.90M
Stochastic %K	57%
Beta	-0.92
Analysts	Strong Sell
Price Target	$19.29